Valerie Askew

Pyrazole inhibitors of HMG-CoA reductase: an attempt to dramatically reduce synthetic complexity through minimal analog re-design.

B. Tait, M. Kowala, G. Lu, 2007, Bioorganic & medicinal chemistry letters.

Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.

G. Lu, J. Pfefferkorn, M. Harris, 2007, Bioorganic & medicinal chemistry letters.

Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.

Yuntao Song, Bruce Auerbach, Lisa Dillon, 2007, Bioorganic & medicinal chemistry letters.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Yuntao Song, Bruce Auerbach, Lisa Dillon, 2008, Bioorganic & medicinal chemistry letters.

Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.

Bruce Auerbach, Lisa Dillon, Jeffrey A Pfefferkorn, 2008, Journal of medicinal chemistry.